CB Insights
Technology Market Intelligence
Technology Market Intelligence
Public list: BIO 2016 (619) Pharma Startups (4734) Rare Diseases (230)
CymaBay Therapeutics, formerly Metabolex, is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, with an emphasis on type 2 diabetes. The company ha...Show all
Company (IPO / Went public)
Phone: 510-293-8800
7999 Gateway Blvd.
Suite 130
Newark, 94560
California, United States
| Total Funding | Date of Last Funding | |
|---|---|---|
| CymaBay Therapeutics | $203.3M | Jul 28, 2014 |
| Intarcia Therapeutics | $1513.7M | Apr 3, 2017 |
| KAI Pharmaceuticals | $63M | Apr 11, 2012 |
| See all 27 competitors | ||
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| Treatment of nafld and nash | Mar 02, 2017 | May 08, 2018 | Patent |
| Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | Jul 26, 2017 | Mar 27, 2018 | Patent |
| Crystalline solid and amorphous forms of (−)-halofenate and methods related thereto | Dec 03, 2015 | Dec 19, 2017 | Patent |
| Treatment of intrahepatic cholestatic diseases | Sep 21, 2016 | Nov 07, 2017 | Patent |
| Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | Nov 18, 2015 | Oct 31, 2017 | Patent |
